Aridis Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARDS research report →
Price Chart
About the company
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies, specifically employing fully human monoclonal antibodies (mAbs) to address severe, life-threatening infections. Their lead product candidate, AR-301, a fully human IgG1 mAb, is currently in pivotal Phase III trials for treating lung infections caused by Staphylococcus aureus alpha toxin.
- CEO
- Vu L. Truong
- IPO
- 2018
- Employees
- 37
- HQ
- Los Gatos, CA, US
Get TickerSpark's AI analysis on ARDS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.46K
- P/E
- -0.00
- Fwd P/E
- 0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 164.69%
- ROIC
- 172.72%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-29,993,000
- Net Income
- $-30,749,000+27.3%
- EPS
- $-1.64+52.3%
- OCF Growth
- -27.0%
- FCF Growth
- -24.5%
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -26.04
- RSI (14)
- 43
- Avg Volume
- 14.44K
No earnings-call transcripts are available for ARDS yet.
- Free Float
- 90.4%
- Shares Outstanding
- 44.57M
- Float Shares
- 40.31M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Minot Wealth Management LLC | 50.00K | 0 |
| B. Riley Wealth Management, Inc. | 10.00K | ▲ 10.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 27, 24 | Windham-Bannister Susan Richards | other | 200,000 |
| Jun 27, 24 | HAMILTON JOHN F | other | 200,000 |
| Jun 27, 24 | Jafri Hasan | other | 250,000 |
| Jun 24, 24 | Patzer Eric | buy | 714,286 |
| Jun 24, 24 | Truong Vu | buy | 714,286 |
| Sep 18, 23 | HAMILTON JOHN F | other | 15,000 |
| Sep 18, 23 | Windham-Bannister Susan Richards | other | 15,000 |
| Sep 18, 23 | Patzer Eric | other | 15,000 |
| Sep 18, 23 | Truong Vu | other | 30,000 |
| Sep 18, 23 | Jafri Hasan | other | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARDS coverage
Recent articles, reports, and earnings notes.
No research on ARDS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARDS report →RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
gurufocus.com · May 31
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
gurufocus.com · May 29
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
globenewswire.com · Mar 31
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
globenewswire.com · Jan 15
Aridis Provides Corporate Update
globenewswire.com · Dec 20
Aridis Provides Corporate Update
globenewswire.com · Jun 24
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
globenewswire.com · Jun 24
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
globenewswire.com · May 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.